Cost–benefit analysis of public reimbursement of semaglutide (Wegovy®) for obesity treatment in Portugal

Loading...

Embargo

2026-12-09

Editor(s)

Coadvisor

Journal Title

Journal ISSN

Volume Title

Publisher

Language
| | |